Schering contrast agent debuts in Sweden:
This article was originally published in Clinica
Schering (Berlin, Germany) has gained approval for its liver specific-contrast agent, Resovist, in Sweden. Schering used the EU's mutual recognition procedure to gain the approval, which marks the worldwide marketing debut of the product. Resovist was developed in collaboration with Japan's Meito Sangyo. It will be launched in Sweden in mid-2001. The agent is injected as an intravenous bolus and can detect and characterise small liver focal lesions, enabling early detection of hepatic carcinoma or metastases. Imaging is immediate, cutting down examination time. Schering claims a 60 % share of world MRI contrast agent sales.
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.